The market value is just over 300 million, which is still underestimated for a phase III clinical drug. It should be at least 500-600 million conservatively and may be close to 1 billion in a bull market before the readout, so it should be at least $1.2 dollars. Of course, cu6 with 1.6 billion market cap just started phase III. The recent rise of DXB is not due to pump and dump, Very reasonable
DXB - Research & Valuation, page-189
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
55.0¢ |
Change
-0.060(9.84%) |
Mkt cap ! $302.3M | |||
| Open | High | Low | Value | Volume |
| 60.5¢ | 61.0¢ | 55.0¢ | $2.309M | 4.010M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 137019 | 55.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 55.5¢ | 22500 | 1 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| DXB (ASX) Chart |